Boteng stock (300363)
The main business of Chongqing Boteng Pharmaceutical Technology Co., Ltd. is chemical raw material drug CDMO, chemical preparation CDMO and biological CDMO business. Mainly committed to providing customized R&D and customized production services for global pharmaceutical enterprises and new drug research and development institutions, including but not limited to process route design, development and optimization, analytical method development, process and analytical verification, process safety assessment, quality research, laboratory tests, pilot tests and commercial production.
Xinkaiyuan (300 109)
Aibo New Open Source (300 109) Pharmaceutical Technology Group Co., Ltd. specializes in fine chemicals and precision medical care. The main products of fine chemical business are: polyvinylpyrrolidone (PVP) series and related intermediates, vinyl methyl ether/maleic anhydride * * * polymers (PVP, Ortiz) and related intermediates, oral care related series, etc. The main products/services of precision medical services include: early tumor screening based on gene sequencing, molecular diagnosis of female diseases, personalized medical services, etc. In September 2009, the company was recognized as a "high-tech enterprise", with the certificate number GR20094 100005 1 and the validity period of 3 years.
Hengrui Pharma (600276)
The main business of jiangsu hengrui Pharmaceutical (600276) Co., Ltd. involves the research and development, production and sales of drugs. The main products are doxib hydrochloride tablets, apatinib mesylate tablets, thiophenic injection, pyrroltinib maleate tablets, karizumab for injection, rimozolomide tosylate for injection, fluzopali capsules, bupropion ethanolamine tablets, iodixanol injection, butorphanol tartrate injection and tolamine. The company is one of the largest R&D and production bases of anti-tumor drugs, surgical drugs and contrast agents in China. The company's products cover anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and other fields. , and has formed a relatively complete product layout, in which the market share of antineoplastic drugs, surgical anesthesia, contrast media and other fields is among the best in the industry. China Pharmaceutical (600056)R&D 2020 product line was released at the National Pharmaceutical Industry Information Annual Meeting. ...
Fosun Pharma (600 196)
Shanghai Fosun Pharma (600 196) (Group) Co., Ltd. is mainly engaged in pharmacy, medical devices, medical diagnosis and medical health services. The main products are core products in the fields of cardiovascular disease treatment, central nervous system disease treatment, blood system disease treatment, metabolic and digestive system disease treatment, anti-infection disease treatment, anti-tumor treatment, raw materials and intermediates. According to the 20 18 list of the top 100 enterprises in China pharmaceutical industry published by People's Republic of China (PRC), China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology, the Group ranked seventh; According to IQVIA's statistics, the sales revenue of hospital prescription drugs produced by the group in 20 19 was ranked 10 in the whole country. As one of the largest manufacturers of antimalarial drugs in the world, the group has become a drug procurement center for global funds, UNICEF, WHO and African countries. ...
Zuo Li Pharmacy (300 18 1)
Zhejiang Zuoli Pharmaceutical Co., Ltd. (300 18 1) is mainly engaged in the research, development, production and sales of medicinal fungi Wuling and Bering series products, Chinese herbal pieces and Chinese herbal formula granules. The company's main products include Wuling series and Bailing tablets, Chinese herbal pieces and Chinese herbal formula granules. According to the comprehensive statistics ranking of OTC manufacturers and products in China in 2020, Wuling Capsule ranked third in the comprehensive statistics of OTC drugs (proprietary Chinese medicines) in China in 2020, and Bering Tablet, a holding subsidiary of Zhu Feng Pharmaceutical, ranked ninth in the comprehensive statistics of OTC drugs (proprietary Chinese medicines) in China in 2020.
Nanhua Biology (000504)
Nanhua Biomedical Co., Ltd. is mainly engaged in "biomedicine" and "energy saving and environmental protection" business. The company's "biomedical" business includes stem cell storage and technical services, stem cell therapy research and so on. The company's "energy saving and environmental protection" business includes EMC contract energy management business, BT business and related product sales, and sewage treatment business.
Huahai pharmacy (60052 1)
Zhejiang Huahai Pharmaceutical (60052 1) Co., Ltd. is a company mainly engaged in the production and sales of raw materials, pharmaceutical intermediates and preparations. The company's main products are Pulitzer, sartan and other hypertension raw materials. The company is the first company in China to pass the FDA preparation certification, and it is in the leading position in the domestic industry in the fields of international GMP certification, overseas registration of preparations and APIs, and international cooperation.
*ST Hejia (300273)
Based on the research, development, manufacture and sales of medical equipment and consumables, Zhuhai Hejia Medical Equipment Co., Ltd. plans, designs and implements medical professional projects for public hospitals at all levels, and builds clinical key disciplines such as cancer centers, rehabilitation centers and intervention centers. The company mainly deals in four business segments: minimally invasive tumor treatment equipment, medical molecular sieve oxygen-making equipment and engineering, routine diagnosis and treatment equipment and medical equipment agent distribution. The company has been recognized as a national high-tech enterprise and a national independent intellectual property enterprise, and has set up a postdoctoral research mobile station in Hengqin New District of Zhuhai (the country) with the approval of the State Bo Guan Office.
Haixin shares (60085 1)
The main business of Shanghai Haixin Group Co., Ltd. is the manufacture and sales of pharmaceutical products, the production and sales of plush fabrics and clothing, the rental of park properties, financial investment and so on. Its main products cover medicine, toys, real estate, warehousing and transportation industries. The company imports Japanese raw materials, engaged in the research and development of plush fabrics, spinning/yarn processing of polyester and acrylic fibers, and the production of plush toys, chemical fiber blankets, clothing and other related textiles. Up to now, it has processed and manufactured chemical raw materials, medicines, biological products, health care products, Chinese medicine raw materials and various preparations, and engaged in investment business and asset management in line with national industrial policies.
New Drugs in Zhao Yan (603 127)
Beijing Zhao Yan New Drug (603 127) Research Center Co., Ltd. focuses on the safety evaluation and monitoring services of drugs throughout their life cycle, and its preclinical drug research services are the core business of the company, including non-clinical drug safety evaluation services, pharmacodynamic research services, animal pharmacokinetics research services and drug screening. The company is the first professional pre-clinical safety evaluation institution for new drugs in China that has passed the FDAGLP inspection in the United States, and has AAALAC (International Association for the Examination and Certification of Laboratory Animal Welfare) certification and China FDAGLP certification. The provided test report and safety data have been approved by FDA of the United States, drug regulatory agencies of other countries in the world and CFDA of China, and are used to support clinical research in their respective countries.